期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 33, 期 12, 页码 1397-+出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2014.58.8848
关键词
-
类别
资金
- National Health and Medical Research Council Australia [1062702]
- Independent Medical Research Institutes Infrastructure Support Scheme
- Cancer Council Victoria (Sir Edward Dunlop Fellowship in Cancer Research)
- Australian Cancer Research Foundation
- Victorian State Government
- V Foundation Translation Research Award
- National Cancer Institute [P50 CA136393]
- Ovarian Cancer Research Fund Program Project Development Grant
- Department of Defense Synergistic Translational Leverage Award
- National Health and Medical Research Council of Australia [1062702] Funding Source: NHMRC
Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive. However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors. We provide an update on PARP inhibitor clinical development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据